Federal Regulatory Stance on Medical Cannabis Use
The landscape surrounding medical cannabis use continues to evolve, with recent federal guidance and legislative proposals impacting various sectors. The Department of Transportation (DOT) has issued guidance stating that truck drivers, pilots, and other safety-sensitive workers remain prohibited from using medical cannabis, irrespective of the Trump administration’s rescheduling decision. The DOT explicitly noted that “Marijuana use is not compatible with safety-sensitive functions,” reinforcing existing federal prohibitions for these roles.
Concurrently, federal lawmakers are addressing the issue of impaired driving. House Transportation and Infrastructure Committee Chairman Sam Graves (R-MO) and Ranking Member Rick Larsen (D-WA) have released proposed legislation. This bill would mandate federal officials to conduct studies on driving under the influence of marijuana and other substances, with the objective of proposing “evidence-based impairment standards.” This initiative reflects a legislative effort to establish clearer regulatory frameworks for cannabis impairment.
Other Federal Developments
- Customs and Border Protection (CBP) included marijuana seizures in its statistics on “drug interdictions that save lives,” indicating continued federal enforcement.
- Representative Brian Mast (R-FL) discussed his House-passed veterans medical cannabis amendment, which aims to expand access for military veterans.
- Representative James Comer (R-KY) toured a hemp business, stating he is developing federal legislation to mitigate “unintended consequences of a prior Senate bill” that have affected the hemp industry.
State Policy and Medical Research Developments
State Legislative Movement
At the state level, policy discussions around medical cannabis use are ongoing. Indiana Governor Mike Braun (R) expressed hope that legislative opposition to medical cannabis legalization would “soften.” Governor Braun highlighted the potential benefits for military veterans for whom other treatments may be ineffective, and noted that Indiana is bordered by states that have already legalized medical cannabis.
Other state legislative and regulatory activities include:
- Minnesota lawmakers advanced legislation to Governor Tim Walz (D) that would revise various cannabis industry rules and require regulators to recommend the creation of a psilocybin therapy program.
- Illinois regulators adopted new rules pertaining to cannabis plant monitoring and associated fees.
- New Jersey regulators engaged in discussions regarding marijuana product testing protocols, market expansion strategies, and labor-related issues within the industry.
Cannabinoid Research and Therapeutics
New research continues to explore the therapeutic potential of cannabinoids. A federally funded study indicated that “chronic cannabinoid exposure, particularly with cannabis extract, reduces body weight, improves glucose homeostasis and normalizes adipose tissue function in a mouse model of” diet-induced obesity. The study specifically found that THC and cannabis extract “robustly reduced body weight and visceral adiposity” in mice with diet-induced obesity.
In veterinary medicine, a case report concluded that the “clinical application of a broad-spectrum Cannabis oil rich in CBD may represent a promising therapeutic alternative for cats affected by feline gingivostomatitis.” These findings contribute to the growing body of evidence on cannabinoid applications beyond human use.
FDA Breakthrough Therapy Status
The Food and Drug Administration (FDA) granted breakthrough therapy status to VERTANICAL’s full-spectrum cannabis extract. This designation is for the treatment of chronic low back pain, potentially accelerating the development and review process for this specific therapeutic application.
Market Activity and Investment Landscape
In the public markets, Glass House Brands Inc. filed a prospectus supplement to its at-the-market distribution program. This filing enables the company to sell up to US$50 million worth of equity shares, providing a mechanism for capital raising. Additionally, Representative Greg Stanton (D-AZ) reported a sale of Trulieve stock valued between US$15,001 and US$50,000 this month, as detailed in financial disclosures.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
